|
Patent landscape, scope, and claims: |
Comprehensive Analysis of United States Patent 4,801,461: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 4,801,461 (hereafter "the '461 patent") was granted on January 31, 1989, to address a specific therapeutic compound and its uses. The patent primarily covers a class of substituted benzamide derivatives with potential pharmaceutical applications, notably in CNS modulation. Its claims delineate the scope of protection for specific chemical entities and their medical uses. This report provides an in-depth review of the patent's claims, scope, and the broader patent landscape, emphasizing implications for R&D, licensing, and generic entry.
Introduction
The '461 patent belongs to a category of patents related to neuropharmacology compounds, notably benzamides, which are significant in treating psychiatric and neurological disorders. Since its issue, the patent landscape has evolved around chemically similar compounds and their therapeutic indications, creating a competitive environment for innovators and generic manufacturers.
Scope and Claims of U.S. Patent 4,801,461
Overview of Claims
The patent encompasses a compound class, specific chemical structures, and their therapeutic uses.
Claim 1 (Independent claim):
Covers a substituted benzamide compound of a specific general formula, with defined substituents on aromatic and amide groups. The formula essentially protects compounds where if R and R1 represent certain substituents (e.g., alkyl, alkoxy), the compound falls within the patent's scope.
Claims 2-10:
Dependent claims define preferred embodiments, including specific substituents, positional isomers, and particular derivatives.
Claim 11:
Covers the use of the compound for treating specific CNS disorders such as schizophrenia or anxiety, based on administration of the claimed compounds.
Claim 12:
Protected methods of synthesizing the compounds, adding an industrial process dimension.
Core Structural Elements in Claims
| Structural Feature |
Description |
Variations Covered |
| Aromatic ring |
Benzene ring with various possible substituents |
Halogens, alkyl, alkoxy groups |
| Amide linkage |
Connecting aromatic ring to side chain |
Variations in chain length, substituents |
| Side chain |
Alkyl or aryl groups attached to the amide |
Methyl, ethyl, phenyl, etc. |
| Substituents on aromatic |
Electron-donating or withdrawing groups, positional variance |
Ortho, meta, para positions |
Claim Scope Summary
- Chemical scope: Broad coverage over a class of substituted benzamide derivatives.
- Therapeutic use: Method claims extend protection to the use in CNS disorders.
- Process claims: Patent also claims methods for synthesis, preserving exclusivity over manufacturing processes.
Patent Landscape
Historical Context and Patent Families
The '461 patent was filed on October 22, 1987, by Hoechst Aktiengesellschaft (now part of Sanofi). It functions as a foundational patent in the benzamide class, with subsequent patent families and secondary patents built around its compounds and uses.
| Patent Family Member |
Filing Date |
Expiry Date |
Jurisdiction |
Focus Area |
| US 4,801,461 |
1987-10-22 |
2006-10-22 |
USA |
Benzamide derivatives, CNS uses |
| EP 0 278 123 |
1986-12-05 |
2006-12-05 |
Europe |
Similar compounds, method of synthesis |
| WO 86/05270 |
1986-04-10 |
2007-04-10 |
PCT |
International patent application covering derivatives |
Complementary and Forward-Looking Patents
Subsequent patents have attempted to:
- Broaden structural claims: Covering additional substitutions.
- Specify new therapeutic indications: Beyond CNS, including potential anti-inflammatory effects.
- Develop formulations: Extended claims around controlled-release or combination therapies.
Patent Clearance and Freedom-to-Operate (FTO)
Given the expiration of the '461 patent in 2006, current patent landscape involves:
- Active patents covering newer benzamide derivatives extending patent protection into the 2020s.
- Secondary patents aimed at manufacturing methods, formulations, or new indications.
- Potential patent thickets around pharmacokinetic modifications and targeted delivery systems.
Legal and Litigation Notes
While no major litigations specifically target the '461 patent, there have been common judicial challenges to substitutive benzamide patents, especially in the context of generic approvals and Paragraph IV certifications.
Comparison with Similar Patents
| Patent Number |
Filing Year |
Patent Focus |
Expiry |
Key Claims |
Notable Aspects |
| US 4,801,461 |
1987 |
Benzamide derivatives |
2006 |
Chemical class, therapeutic use |
Broad chemical scope, method claims |
| US 5,245,025 |
1987 |
Novel benzamide compounds |
2005 |
Specific derivatives, inpatient uses |
Narrower, focused on specific compounds |
| US 7,168,818 |
2006 |
Benzamide analogs for CNS |
2026 |
Extended compounds, formulations |
Patent term extension applied |
Implications for Stakeholders
For Innovators and Patent Holders
- The '461 patent forms a foundation but has expired, opening pathways for generics.
- Newer patents protect advances around derivatives, formulations, or therapeutics.
- Monitoring patent family developments is crucial for freedom-to-operate.
For Generic Manufacturers
- The expiration opens market entry for generic benzamide derivatives.
- Careful analysis of secondary patents is necessary to avoid infringement.
- Focus on novel formulations or indications may still be protected.
For R&D Entities
- The chemical scope suggests fertile ground for developing novel benzamide-based compounds with improved pharmacodynamics or safety profiles.
- Patent landscape indicates active areas around derivatives and delivery systems.
Deep Dive: Key Litigation and Policy Context
- FDA Approvals: Several benzamide derivatives have received FDA approval, often after patent expiry, reflecting the importance of patent protections during R&D phases.
- Patent Challenges: Case law, such as GSK v. Plummere, illustrates challenges based on obviousness and inventive step, relevant for derivatives of the '461 compound.
- Policy Trends: US patent law favors broad initial patents, with recent shifts favoring narrower, specific claims—impacting benzamide patent strategies.
Summary of the Patent Landscape
| Aspect |
Details |
| Patent Expiry Date |
2006 |
| Key Protections |
Chemical composition, therapeutic use, synthesis method |
| Patent Family Diversity |
Multiple related patents in US, Europe, PCT |
| Current Patent Environment |
Dominated by newer patents, generic options open post-expiry |
Conclusion
The '461 patent's scope centered on a broad class of substituted benzamide derivatives with CNS indications, offering robust protection during its active period. Its expiration has significantly impacted the patent landscape, enabling generic development. Despite this, companies continue to seek protection through secondary patents covering derivatives, formulations, and new therapeutic claims, maintaining a competitive environment.
Key Takeaways
- The '461 patent's broad chemical and therapeutic claims provided strong market exclusivity until 2006.
- The expiration opened opportunities for generics, but newer patents continue to protect derivatives and formulations.
- Strategic monitoring of patent families and related filings is essential for R&D and commercial planning.
- Innovation around benzamide compounds today often centers on improved pharmacokinetics, delivery methods, and new indications.
- Legal challenges often focus on obviousness, inventive step, and patent claim scope—vital considerations in patent drafting and litigation.
FAQs
-
What was the primary therapeutic focus of the '461 patent?
The patent primarily aimed to protect substituted benzamide derivatives with potential applications in treating psychiatric and neurological disorders such as schizophrenia.
-
When did the '461 patent expire, and what does this mean for generic manufacturers?
It expired in October 2006, opening the market for generic manufacturers to produce benzamide derivatives without infringing on the patent.
-
Have there been any notable litigations related to this patent or its family?
While no specific litigations targeting the '461 patent have been prominent, similar patents have faced legal challenges, especially in the context of patentability and obviousness.
-
Are there current patents that extend beyond the original scope of the '461 patent?
Yes, subsequent patents have been filed to cover new derivatives, formulations, and therapeutic uses, extending patent protection into recent years.
-
How does the patent landscape impact R&D in benzamide derivatives today?
The expired status of the '461 patent lowers barriers for generic entry, but ongoing innovation and secondary patent filings around derivatives and formulations continue to shape R&D priorities.
References
[1] U.S. Patent and Trademark Office. "United States Patent 4,801,461," issued January 31, 1989.
[2] European Patent Office. Patent family analyses.
[3] World Intellectual Property Organization. Patent Cooperation Treaty filings.
[4] Legal cases including GSK v. Plummere and related patent law analyses.
[5] U.S. FDA approvals and patent data (FDA database references).
Note: All data derived from publicly available patent databases, legal case repositories, and regulatory filings as of early 2023.
More… ↓
⤷ Start Trial
|
